[{"address1": "2265 Upper Middle Road East", "address2": "Suite 602", "city": "Oakville", "state": "ON", "zip": "L6H 0G5", "country": "Canada", "phone": "289-910-0850", "fax": "905-481-2394", "website": "https://www.cardiolrx.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. David G. Elsley MBA", "title": "President, CEO & Director", "fiscalYear": 2023, "totalPay": 549704, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA", "title": "CFO, Corporate Secretary & Director", "fiscalYear": 2023, "totalPay": 216619, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bernard  Lim B.Sc.", "title": "Chief Operating Officer", "fiscalYear": 2023, "totalPay": 379083, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew Warwick Hamer M.D.", "age": 61, "title": "Chief Medical Officer & Head of Research & Development", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 548574, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Trevor  Burns", "title": "Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.18, "open": 2.2, "dayLow": 2.1508, "dayHigh": 2.2899, "regularMarketPreviousClose": 2.18, "regularMarketOpen": 2.2, "regularMarketDayLow": 2.1508, "regularMarketDayHigh": 2.2899, "forwardPE": -7.2903223, "volume": 125502, "regularMarketVolume": 125502, "averageVolume": 339803, "averageVolume10days": 370620, "averageDailyVolume10Day": 370620, "bid": 2.25, "ask": 2.28, "bidSize": 100, "askSize": 400, "marketCap": 155936160, "fiftyTwoWeekLow": 0.63, "fiftyTwoWeekHigh": 2.41, "fiftyDayAverage": 1.8396, "twoHundredDayAverage": 1.224725, "currency": "USD", "enterpriseValue": 118219528, "floatShares": 64226620, "sharesOutstanding": 68998304, "sharesShort": 328056, "sharesShortPriorMonth": 326642, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0047999998, "heldPercentInsiders": 0.044159997, "heldPercentInstitutions": 0.12993, "shortRatio": 1.14, "shortPercentOfFloat": 0.005, "impliedSharesOutstanding": 68499000, "bookValue": 0.298, "priceToBook": 7.5838923, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -30218588, "trailingEps": -0.35, "forwardEps": -0.31, "enterpriseToEbitda": -3.914, "52WeekChange": 2.2106037, "SandP52WeekChange": 0.28043115, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CRDL", "underlyingSymbol": "CRDL", "shortName": "Cardiol Therapeutics Inc.", "longName": "Cardiol Therapeutics Inc.", "firstTradeDateEpochUtc": 1547562600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ee9d962b-eed4-3063-8df9-c815990fe5d8", "messageBoardId": "finmb_424954803", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.26, "targetHighPrice": 8.99, "targetLowPrice": 6.0, "targetMeanPrice": 7.49, "targetMedianPrice": 7.49, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 28572976, "totalCashPerShare": 0.425, "ebitda": -30206168, "totalDebt": 167136, "quickRatio": 2.646, "currentRatio": 2.807, "debtToEquity": 0.833, "returnOnAssets": -0.45347, "returnOnEquity": -0.92109, "freeCashflow": -10193911, "operatingCashflow": -22156452, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-05-21"}]